USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

A recent research presented at the ENDO 2025 revealed that high blood sugar levels can impact men's sexual health. The ...

A recent study conducted on medical students by Peruvian researchers found that there may be a link between a chronic gastrointestinal disorder and erectile dysfunction (ED).. The study, published ...

UTMB Health study says erectile dysfunction meds associated with reductions — but not where you might think 😅 Ahmed Humble , Digital Content Producer Published: November 19, 2024 at 11:38 AM ...

Erectile dysfunction (ED) affects up to 66% of diabetic men globally, with risk factors like age, long-term diabetes, and obesity playing a significant role. The study emphasizes the urgent need ...

The study, which involved more than 1,000 prediabetic patients, found that those taking the highest dose of 15 mg lost 23% of their body weight, while those on a placebo lost just 2%. Tirzepatide is ...

A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity. PR Newswire . Thu, Aug 1, 2024, 6:45 AM 19 min read.